Niagen Bioscience reports Q1 EPS 7c, consensus 2c

Reports Q1 revenue $30.5M, consensus $27.1M. “We are proud to start the year with another record quarter, delivering $30.5 million in net sales, a 38% year-over-year growth fueled by both Tru Niagen(R) and strong Niagen(R) ingredient demand, a 63.4% gross margin, and $5.1 million in net income,” said Niagen Bioscience (NAGE) CEO Rob Fried. “With strong momentum heading into 2025, and with the launch of our new brand identity and expansion of our NAD+ precursor patent portfolio, we are reinforcing a powerful foundation for the future of healthy aging and are energized by the market’s growing trust in Niagen.”